Dextech Medical AB (XSAT:DEX)

Market Cap	210.74M +190.8%
Revenue (ttm)	3.07M -38.4%
Net Income	-5.63M
EPS	-0.30
Shares Out	18.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,339
Average Volume	12,343
Open	11.30
Previous Close	11.20
Day's Range	10.90 - 11.80
52-Week Range	3.62 - 14.40
Beta	1.51
RSI	58.73
Earnings Date	Feb 25, 2026

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. The company’s lead candidate, OsteoDex that has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine tumors,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 1
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: DEX

Financial Performance

In fiscal year 2025, Dextech Medical AB's revenue was 3.22 million, a decrease of -40.15% compared to the previous year's 5.39 million. Losses were -4.84 million, 2.96% more than in 2024.